ReviewInternational journal of molecular sciences2017
Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs.International journal of molecular sciences · 2024Pooled it
- Study of FOXO1/pFOXO1, lncRNA ADAMTS9-AS2, and miR-96-5p in laryngeal squamous cell carcinoma.BMC cancer · 2025Article
- In vivo validation of the functional role of MicroRNA-4638-3p in breast cancer bone metastasis.Journal of cancer research and clinical oncology · 2024Article
- Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy.International journal of molecular sciences · 2024Article
- The role of miRNAs as biomarkers in breast cancer.Frontiers in oncology · 2024Review
- Circ_0067934: a circular RNA with roles in human cancer.Human cell · 2023Review
- Crosstalk between long noncoding RNA and microRNA in Cancer.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- MicroRNAs within the Basal-like signature of Quadruple Negative Breast Cancer impact overall survival in African Americans.Scientific reports · 2022Article
- Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer.Scientific reports · 2022Article
- A microRNA panel that regulates proinflammatory cytokines as diagnostic and prognosis biomarkers in colon cancer.Biochemistry and biophysics reports · 2022Article
- Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?Discover oncology · 2022Article
- The Implication of microRNAs as non-invasive biomarkers in 179 Egyptian breast cancer female patients.Oncology research · 2022Article
- Is there a correlation between miR-301a expression and neoadjuvant chemotherapy efficacy in breast cancer tissue?Biochemistry and biophysics reports · 2021Article
- Article
- Mechanisms of Taxane ResistanceCancers · 2020Review
- How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects.International journal of molecular sciences · 2020Review
- Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer.Cancers · 2020Review
- Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases.Biomolecules · 2020Review
- Urinary Exosomal MicroRNAs as Potential Non-invasive Biomarkers in Breast Cancer Detection.Molecular diagnosis & therapy · 2020Article
- miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments.International journal of molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in diagnosis and new treatments such as targeted therapies, breast cancer (BC) is still the most prevalent tumor in women worldwide and the leading cause of death. The principal obstacle for successful BC treatment is the acquired or de novo resistance of the tumors to the systemic therapy (chemotherapy, endocrine, and targeted therapies) that patients receive. In the era of personalized treatment, several studies have focused on the search for biomarkers capable of predicting the response to this therapy; microRNAs (miRNAs) stand out among these markers due to their broad spectrum or potential clinical applications. miRNAs are conserved small non-coding RNAs that act as negative regulators of gene expression playing an important role in several cellular processes, such as cell proliferation, autophagy, genomic stability, and apoptosis. We reviewed recent data that describe the role of miRNAs as potential predictors of response to systemic treatments in BC. Furthermore, upon analyzing the collected published information, we noticed that the overexpression of miR-155, miR-222, miR-125b, and miR-21 predicts the resistance to the most common systemic treatments; nonetheless, the function of these particular miRNAs must be carefully studied and further analyses are still necessary to increase knowledge about their role and future potential clinical uses in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.